WO2012093165A1 - Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine - Google Patents
Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine Download PDFInfo
- Publication number
- WO2012093165A1 WO2012093165A1 PCT/EP2012/050174 EP2012050174W WO2012093165A1 WO 2012093165 A1 WO2012093165 A1 WO 2012093165A1 EP 2012050174 W EP2012050174 W EP 2012050174W WO 2012093165 A1 WO2012093165 A1 WO 2012093165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperazine
- chloro
- indan
- phenyl
- acid
- Prior art date
Links
- BYPMJBXPNZMNQD-PZJWPPBQSA-N CC(C)(C1)N(C)CCN1[C@H](C1)c2cc(Cl)ccc2[C@@H]1c1ccccc1 Chemical compound CC(C)(C1)N(C)CCN1[C@H](C1)c2cc(Cl)ccc2[C@@H]1c1ccccc1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 description 1
- FBCSWIXKXHSYBN-AZUAARDMSA-N CC(C)(C1)NCCN1[C@H](C[C@H]1c2ccccc2)c2c1ccc(Cl)c2 Chemical compound CC(C)(C1)NCCN1[C@H](C[C@H]1c2ccccc2)c2c1ccc(Cl)c2 FBCSWIXKXHSYBN-AZUAARDMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
Definitions
- the present invention relates to resolution methods for manufacture of 4-((lR,3 S)-6- chloro-3 -phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and 1 -(( 1 R, 3 S)-6-chloro-3 - phenyl-indan-l-yl)-3,3-dimethyl-piperazine and pharmaceutically acceptable salts thereof.
- the compounds of the present invention 4-((lR,3S)-6-chloro-3 -phenyl-indan- 1-yl)- 1,2,2-trimethyl-piperazine (I) and l-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine (II) hereinafter referred to as Compound (I) and (II) have the respective molecular structures depicted below.
- a group of trans isomers of 3-aryl-l-(l-piperazinyl)indanes substituted in the 2- and/or 3-position of the piperazine ring has been described in WO 93/22293 and in Klaus P. Boges0, Drug Hunting, the Medicinal Chemistry of l-Piperazino-3- phenylindans and Related Compounds, 1998, ISBN 87-88085-10-4 (cf. e.g. compound 69 in table 3, p. 47 and in table 9A, p. 101).
- the compounds are described as having high affinity for dopamine Di and D 2 receptors and the 5-HT 2 receptor and are suggested to be useful for treatment of several diseases in the central nervous system, including schizophrenia.
- Trans racemic 4-((6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and trans racemic l-(6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine may e.g. be synthesized analogously to the methods outlined in Bogeso et al., J. Med. Chem., 1995, 38, p. 4380-4392 and in WO 93/22293.
- Manufacture of Compound (I) by resolution of trans racemic 4-((6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine has been described by Bogeso et al.
- Compound (I) is a potent Di/D 2 antagonists showing some Di selectivity in vitro while in vivo it is equipotent as Di and D 2 antagonist.
- the compound is also described as a potent 5-HT 2 antagonist and as having high affinity for ai adrenoceptors.
- Compound (II) displays a similar receptor profile and pharmacological activity as Compound (I). Summary of the invention
- the present inventors have found that a high yield and a high enantiomeric excess of 4-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and 1-((1R,3S)- 6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine can be obtained by resolution of their respective racemates by the careful selection of a suitable enantiomerically pure acid and a solvent.
- the resolution methods of the present invention have been found to provide a yield of at least about 30 % under certain circumstances up to more than 45 % which is strikingly higher than the yield obtained by the resolution method described in B0geso et al., J. Med. Chem., 1995, 38, p. 4380-4392 wherein (+)-ditoluoyl tartaric acid is used for resolution of trans racemic 4-(6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine.
- the problem set out to be solved by the present invention is the resolution of trans racemic 4-(6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and trans racemic l-(6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine) into the respective enantiomeric compounds, 4-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine and l-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine.
- the enantiomeric excess is at least about 30%, either in the solid phase (resolution) or in the liquid phase (reverse resolution).
- the enantiomeric compounds i.e. 4-((lR,3S)-6-chloro-3-phenyl-indan-l- yl)-l,2,2-trimethyl-piperazine and l-((lR,3S)-6-chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine, respectively, are crystallized in the solid phase.
- the present invention relates to processes wherein the racemate is mixed with an enantiomerically pure acid in a solvent.
- the mixture may optionally be heated to an appropriate temperature to obtain a solution of the racemate and the enantiomerically pure acid.
- Subsequent precipitation of the enantiomers may be obtained e.g. by cooling or evaporation and the precipitate may be isolated and optionally dried. It is the experience of the inventors that recrystallisation of the precipitate may increase the enantiomeric excess.
- the choice of solvent and conditions for the resolution process e.g. temperature and stoichiometry of the starting materials may be used to optimize the yield and enantiomeric excess of the desired enantiomer.
- the present invention clearly also covers the process of reverse resolution where the antipode of fr «5 , -4-((lR,3S)-6-chloro-3-phenylindan-l-yl)-l,2,2-trimethyl piperazine or the antipode of iram-l-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine is crystallised in high ee.
- 4-((lR,3 S)-6-chloro- 3-phenylindan-l-yl)-l,2,2-trimethyl piperazine or tra3 ⁇ 4s-l-((lR,3 S)-6-chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine can be isolated from the liquid phase, e.g. in the form of a salt or a free base.
- trans racemic 4-((6-chloro-3-phenyl-indan-l-yl)- 1,2,2- trimethyl-piperazine refers to the racemate of 4-((lR,3 S)-6-chloro-3-phenylindan-l- yl)-l,2,2-trimethyl piperazine and 4-((l S,3R)-6-chloro-3-phenylindan-l-yl)-l,2,2- trimethyl piperazine.
- the same principle applies for "trans racemic l-(6-chloro-3- phenyl-indan- 1 -yl)-3 , 3 -dimethyl-piperazine” .
- a “racemate” refers to an equal mixture of non-superimposable mirror images.
- resolution shall also cover the process of reverse resolution.
- yield is calculated base on the total mass of the salts of the racemate in the process; it is thereby understood that the maximum yield of a pure enantiomer can not exceed 50% when starting from a racemate.
- Compound (I) and Compound (II) respectively is intended to designate any form of the compound, such as the free base, pharmaceutically acceptable salts thereof, e.g. pharmaceutically acceptable acid addition salts, such as succinate and malonate salts, hydrates or solvates of the free base or salts thereof, as well as anhydrous forms, amorphous forms, or crystalline forms.
- pharmaceutically acceptable acid addition salts such as succinate and malonate salts, hydrates or solvates of the free base or salts thereof, as well as anhydrous forms, amorphous forms, or crystalline forms.
- the term “enantiomerically pure acid” is defined as an acid in which at least 95% of the enantiomeric part of the acid is one of a pair of non- superimposable mirror images.
- a pharmaceutically acceptable salt of a compound of Formula I or II includes pharmaceutically acceptable acid addition salts.
- Acid addition salts include salts of inorganic acids as well as organic acids.
- suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the
- the terms “resolution” and “reverse resolution” describes a process by which a racemate is separated into its two enantiomers.
- heating to an "appropriate temperature” indicates that the composition is heated to a temperature suitable for obtaining a solution, such as above room temperature such as above 40°C, such as above 45°C, such as above 50°C, such as above 55°C, such as above 60°C, such as above 65°C, such as above 70°C limited by the reflux temperature of the solvent.
- Dependent on the solvent used "appropriate temperature” might indicate reflux temperature, i.e. the composition is heated at reflux.
- reflux is a technique involving the condensation of vapors and the return of this condensate to the system from which it originated.
- recrystallization is a procedure for purifying compounds. Recrystallization can be performed by e.g. single-solvent recrystallization, multi- solvent recrystallization or hot filtration-recrystallization.
- enantiomeric excess is abbreviated ee and defined as the absolute difference between the mole fractions of each enantiomer of a compound.
- the present invention relates to a process for the manufacture of 4-((lR,3 S)-6-chloro- 3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine (Compound (I)) comprising resolution of iram-4-((6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine with suitable enantiomerically pure acid in the presence of a solvent.
- the present invention relates in a first embodiment (El) to a process for the manufacture of 4-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine (Compound (I)) comprising resolution of fr- ⁇ ms-4-((6-chloro-3-phenyl- indan-l-yl)-l,2,2-trimethyl-piperazine with suitable enantiomerically pure acid in the presence of a solvent, wherein the enantiomerically pure acid is selected from the group consisting of dibenzoyl-L-tartaric acid, (S)-chlorophos, dibenzoyl-D-tartaric acid and (R)-chlorophos.
- the solvent comprises at least 30% of one or more of the solvents selected from the group consisting of C3-C8 ketones, C 1 -C5 esters of acetic acid, C 1 -C5 esters of propiotic acid, C 1 -C4 alcohols and C 2 -C3 nitriles.
- the solvent comprises at least 35% or more, such as at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% or 100% of one or more of the solvents selected from the group consisting of C3-C8 ketones, C 1 -C5 esters of acetic acid, C1-C5 esters of propionic acid, C1-C4 alcohols and C2-C3 nitriles.
- the solvent of the process of any of embodiment (El) or (E2) is selected from the group consisting of 2-butanone (MEK), ethyl acetate (EtOAc) and acetonitrile (ACN).
- the enantiomerically pure acid is Dibenzoyl-L-tartaric and the solvent is acetonitrile; or the enantiomerically pure acid is Dibenzoyl-L-tartaric and the solvent is 2-butanone; or the enantiomerically pure acid is Dibenzoyl-L-tartaric and the solvent is ethyl acetate, or the enantiomerically pure acid is Dibenzoyl-D-tartaric and the solvent is acetonitrile; or the enantiomerically pure acid is Dibenzoyl-D-tartaric and the solvent is 2-butanone; or the enantiomerically pure acid is Dibenzoyl-D-tartaric and the solvent is ethyl acetate.
- any of embodiment (El), (E2), or E(3) the enantiomerically pure acid is (S)-Chlorophos and the solvent is acetonitrile; or the enantiomerically pure acid is (S)-Chlorophos and the solvent is 2-butanone; or the enantiomerically pure acid is (S)-Chlorophos and the solvent is ethyl acetate, or the enantiomerically pure acid is (R)-Chlorophos and the solvent is acetonitrile; or the enantiomerically pure acid is (R)-Chlorophos and the solvent is 2-butanone; or the enantiomerically pure acid is (R)-Chlorophos and the solvent is ethyl acetate.
- step e) optionally drying the precipitate obtained in d); f) optionally isolating 4-((lR,3S)-6-chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine at an appropriate temperature from the liquid obtained after step d) if the precipitate obtained in step a), b), or c) is a salt of 4- ((l S,3R)-6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine;
- the process comprises a subsequent step in which the precipitate is recrystallised after step d) or e) or f).
- the isolated 4-((lR,3 S)-6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine is an intermediate.
- the salt of 4-((lR,3 S)-6- chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine is a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt preferably is selected from the list of pharmaceutically acceptable salt in the section Definitions of the present application.
- the isolated 4-((lR,3S)-6-chloro-3- phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine is in the form of a salt which is dissolved in a solvent and recrystallized as a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt preferably is selected from the list of pharmaceutically acceptable salt in the section Definitions of the present application.
- the appropriate temperature of step b) is about 40°C or higher, such as about 45°C, preferably about 50°C or about 55°C or higher such as about 60°C, such as about 65°C, such as about 70°C.
- the solution is cooled to a temperature of about 25°C or lower, such as about 20°C, or 15°C, preferably about 10°C or lower, such as about 5°C or 0°C.
- the present invention also relates to a process for manufacture of l-((lR,3 S)-6- chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (Compound (II)) comprising resolution of iram-l-(6-chloro-3 -phenyl-indan- 1-yl)- 3,3-dimethyl-piperazine with suitable enantiomerically pure acid in the presence of a solvent.
- the present invention relates in an embodiment (El 5) to a process for the manufacture of 1 -(( 1 R, 3 S)-6-chloro-3 -phenyl-indan- 1 -yl)-3 ,3 -dimethyl-piperazine comprising resolution of trans-l -(6-chloro-3 -phenyl-indan- 1-yl)- 3,3-dimethyl- piperazine with suitable enantiomerically pure acid in the presence of a solvent, wherein the enantiomerically pure acid is selected from the group consisting of diisopropylidene-2-keto-L-gulonic acid, diisopropylidene-2-keto-D-gulonic acid, (S)- (+)-l, l '-binaphthyl-2,2'-diyl hydrogenphosphate, (R)-(-)-l, l '-binaphthyl-2,2'-diyl hydrogenphosphate, (R)-(
- the solvent comprises at least 30% of one or more of the solvents selected from the group consisting of C3-C8 ketones, C1-C5 esters of acetic acid, C1-C5 esters of propiotic acid, C1-C4 alcohols and C2-C 3 nitriles.
- the solvent comprises at least 35% or more, such as at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% or 100% of one or more of the solvents selected from the group consisting of C 3 -C 8 ketones, C1-C5 esters of acetic acid, C1-C5 esters of propiotic acid, C1-C4 alcohols and C2-C 3 nitriles
- the solvent of the process of any of embodiment (El 5) and (El 6) is selected from the group consisting of 2-butanone (MEK), ethyl acetate (EtOAc), methanol (MeOH) and acetonitrile (ACN).
- MEK 2-butanone
- EtOAc ethyl acetate
- MeOH methanol
- ACN acetonitrile
- the enantiomerically pure acid is dibenzoyl-L-tartaric and the solvent is acetonitrile; or the enantiomerically pure acid is diisopropylidene-2-keto-L-gulonic acid and the solvent is methanol; or the enantiomencally pure acid is diisopropylidene-2-keto-L-gulonic acid and the solvent is acetonitrile; or the enantiomerically pure acid is (S)-(+)-l, l '-binaphthyl-2,2'-diyl hydrogenphosphate and the solvent is ethyl acetate; or the enantiomerically pure acid is (S)-Chlorophos and the solvent is ethyl acetate; or the enantiomerically pure acid is N-acetyl-L-leucine and the solvent is ethyl acetate; or
- the enantiomerically pure acid is (S)-(+)-l, l '-binaphthyl-2,2'-diyl hydrogenphosphate and the solvent is ethyl acetate.
- step f) optionally isolating l-((lR,3S)-6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine at an appropriate temperature from the liquid obtained after step d) if the precipitate obtained in step a), b), or c) is a salt of l-((l S,3R)-6-chloro-3- phenyl-indan- 1 -yl)-3 , 3 -dimethyl-piperazine;
- the process comprises a subsequent step in which the precipitate is recrystallised after step d) or e) or f).
- the salt of l-((lR,3S)-6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine is a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt preferably is selected from the list of pharmaceutically acceptable salt in the section Definitions of the present application.
- the isolated l-((lR,3 S)-6-chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine is in the form of a salt which is dissolved in a solvent and recrystallized as a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt preferably is selected from the list of
- the appropriate temperature of step b) is about 40°C or higher, such as about 45°C, preferably about 50°C or about 55°C or higher such as about 60°C, such as about 65°C, such as about 70°C.
- the solution is cooled to a temperature of about 25°C or lower, such as about 20°C, or 15°C, preferably about 10°C or lower, such as about 5°C or 0°C.
- X-Ray Powder Diffraction patterns were collected on a Bruker D8 diffractometer using Cu K radiation (40 kV, 40 mA), ⁇ - 2 ⁇ goniometer, and divergence of V4 and receiving slits, a Ge monochromator and a Lynxeye detector.
- the instrument is performance checked using a certified Corundum standard (NIST 1976).
- the software used for data collection was Diffrac Plus XRD Commander v2.5.0 and the data were analysed and presented using Diffrac Plus EVA vl 1.0.0.2 or vl3.0.0.2.
- NMR spectra were collected on a Bruker 400MHz instrument equipped with an auto- sampler and controlled by a DRX400 console. Automated experiments were acquired using ICON-NMR v4.0.4 running with Topspin vl .3 using the standard Bruker loaded experiments. For non-routine spectroscopy, data were acquired through the use of Topspin alone.
- DSC data were collected on a TA Instruments Q2000 equipped with a 50 position auto-sampler.
- the calibration for thermal capacity was carried out using sapphire and the calibration for energy and temperature was carried out using certified indium.
- the instrument control software was Advantage for Q Series v2.8.0.392 and Thermal Advantage v4.8.3 and the data were analysed using Universal Analysis v4.4A.
- TGA data were collected on a TA Instruments Q500 TGA, equipped with a 16 position auto-sampler.
- the instrument was temperature calibrated using certified Alumel and Nickel Typically 5 - 10 mg of each sample was loaded onto a pre-tared aluminium DSC pan and heated at 10 °C/min from ambient temperature to 250-350 °C. A nitrogen purge at 60 ml/min was maintained over the sample.
- the instalment control software was Advantage for Q Series v2.8.0.392 and Thermal Advantage v4.8.3 and the data were analysed using Universal Analysis v4.4A.
- Example 1 Resolution of 4-((lR, 3 S)-6-chloro-3-phenyl-indan-l-yl)-L2,2-trimethyl- piperazine using f"RJj ) -dibenzoyl-L-tartaric acid (L-BDT)
- the system was then subjected to a cooling ramp from 50°C to 0°C at 0.1 °C / min, then held at 0°C for 3 hours prior to be heated to 25°C at 2°C / minute.
- Example 5 1 -(( 1 R,3 S)-6-chloro-3 -phenyl-indan- 1 -yl)-3 , 3 -dimethyl-piperazine Diisopropylidene-2-keto-L-gulonate, methanol
- Example 6 1 -((I R3 S)-6-chloro-3 -phenyl-indan- 1 -yl)-3 , 3 -dimethyl-piperazine Diisopropylidene-2-keto-L-gulonate, acetonitrile
- Example 7 l-((lR.3 S)-6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (SV (+)-! '-binaphthyl-2,2'-diyl hydrogenphosphate salt ethyl acetate
- the system was then subjected to a cooling ramp from 50°C to 0°C at 0.1°C / min, then held at 0°C for 3 hours prior to be heated to 25°C at 2°C / minute.
- the suspension was left under stirring at 25°C for 65 hours, and the product was filtered under vacuum.
- the resulting fresh filtered cake was washed with ethyl acetate (2 mL) prior to be dried in the hood at room temperature. Yield 190.5 mg (47.1%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012204839A AU2012204839A1 (en) | 2011-01-07 | 2012-01-06 | Method for resolution of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan- 1-yl)-3,3-dimethyl-piperazine |
EP12700382.0A EP2661427A1 (en) | 2011-01-07 | 2012-01-06 | Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine |
CA2823103A CA2823103A1 (en) | 2011-01-07 | 2012-01-06 | Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine |
JP2013547863A JP2014501771A (en) | 2011-01-07 | 2012-01-06 | 4-((1R, 3S) -6-chloro-3-phenyl-indan-1-yl) -1,2,2-trimethyl-piperazine and 1-((1R, 3S) -6-chloro-3-phenyl -Method for resolution of indan, 1-yl) -3,3-dimethyl-piperazine |
US13/933,198 US20130331575A1 (en) | 2011-01-07 | 2012-01-06 | Method for resolution of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine |
CN2012800047149A CN103429577A (en) | 2011-01-07 | 2012-01-06 | Method for resolution of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161430552P | 2011-01-07 | 2011-01-07 | |
US61/430,552 | 2011-01-07 | ||
DKPA201100011 | 2011-01-07 | ||
DKPA201100011 | 2011-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012093165A1 true WO2012093165A1 (en) | 2012-07-12 |
Family
ID=45495932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/050174 WO2012093165A1 (en) | 2011-01-07 | 2012-01-06 | Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130331575A1 (en) |
EP (1) | EP2661427A1 (en) |
JP (1) | JP2014501771A (en) |
CN (1) | CN103429577A (en) |
AU (1) | AU2012204839A1 (en) |
CA (1) | CA2823103A1 (en) |
WO (1) | WO2012093165A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014096151A2 (en) | 2012-12-19 | 2014-06-26 | H. Lundbeck A/S | 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof |
WO2020114853A1 (en) | 2018-12-03 | 2020-06-11 | H. Lundbeck A/S | Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR110150A1 (en) * | 2016-11-09 | 2019-02-27 | Roivant Sciences Gmbh | PROCESSES FOR THE PREPARATION OF TPH1 INHIBITORS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022293A1 (en) | 1992-04-28 | 1993-11-11 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
WO2005016901A1 (en) | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
WO2006086984A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Process for making trans-1-((1r, 3s)-6-chloro-3-phenylindan-1-yl)-3, 3-dimethylpiperazine |
WO2006086985A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
WO2011003423A1 (en) * | 2009-07-07 | 2011-01-13 | H. Lundbeck A/S | Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108342C2 (en) * | 2003-08-18 | 2015-04-27 | METHOD OF PREPARATION OF 4 - ((1R, 3S) -6-CHLORO-3-PHENYLINDAN-1-IL) -1,2,2-TRIMETHYLPIPERASINE OR ITS SALT (OPTIONS), CIS- (1S, 3S) -6-CHLORINE 3-PHENYLINDAN-1-OL, CIS- (1S, 3S) -3-REPLACED-5-CHLORINE-1-PHENYLINDAN AND TRANS-1 - ((1R, 3S) -6-CHLORINE-3-PHENYLINDAN-1-IL ) -3,3-DIMETHYLPIPERASINE | |
TW200640891A (en) * | 2005-02-16 | 2006-12-01 | Lundbeck & Co As H | Tartrate and malate salts of a pharmarceutical compound |
-
2012
- 2012-01-06 JP JP2013547863A patent/JP2014501771A/en active Pending
- 2012-01-06 EP EP12700382.0A patent/EP2661427A1/en not_active Withdrawn
- 2012-01-06 CN CN2012800047149A patent/CN103429577A/en active Pending
- 2012-01-06 US US13/933,198 patent/US20130331575A1/en not_active Abandoned
- 2012-01-06 WO PCT/EP2012/050174 patent/WO2012093165A1/en active Application Filing
- 2012-01-06 AU AU2012204839A patent/AU2012204839A1/en not_active Abandoned
- 2012-01-06 CA CA2823103A patent/CA2823103A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022293A1 (en) | 1992-04-28 | 1993-11-11 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
WO2005016901A1 (en) | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
WO2005016900A1 (en) | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
WO2006086984A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Process for making trans-1-((1r, 3s)-6-chloro-3-phenylindan-1-yl)-3, 3-dimethylpiperazine |
WO2006086985A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
WO2011003423A1 (en) * | 2009-07-07 | 2011-01-13 | H. Lundbeck A/S | Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine |
Non-Patent Citations (3)
Title |
---|
BOGESO ET AL., J. MED. CHEM., vol. 38, 1995, pages 4380 - 4392 |
KLAUS P. BOGESO; DRUG HUNTING, THE MEDICINAL CHEMISTRY OF 1-PIPERAZINO-3-PHENYLINDANS AND RELATED COMPOUNDS, 1998 |
See also references of EP2661427A1 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014096151A2 (en) | 2012-12-19 | 2014-06-26 | H. Lundbeck A/S | 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof |
WO2020114853A1 (en) | 2018-12-03 | 2020-06-11 | H. Lundbeck A/S | Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine |
Also Published As
Publication number | Publication date |
---|---|
AU2012204839A1 (en) | 2013-08-22 |
EP2661427A1 (en) | 2013-11-13 |
JP2014501771A (en) | 2014-01-23 |
US20130331575A1 (en) | 2013-12-12 |
CA2823103A1 (en) | 2012-07-12 |
CN103429577A (en) | 2013-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8969558B2 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
KR101731739B1 (en) | Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | |
US20200354363A1 (en) | Crystalline linagliptin intermediate and process for preparation of linagliptin | |
US9518020B2 (en) | Process for Regorafenib | |
JP2020502077A (en) | R-6-hydroxy-8- [1-hydroxy-2- [2- (4-methoxyphenyl) -1,1-dimethylethylaminoethyl] -2H-1,4-benzoxazin-3 (4H) -one Improved process for producing hydrochloride | |
CA2134630A1 (en) | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives | |
WO2012093165A1 (en) | Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine | |
US8779145B2 (en) | Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline | |
US8501947B2 (en) | Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine | |
KR101530924B1 (en) | Separation of triazine derivatives enantiomers using tartaric acid | |
CN109414429B (en) | Process for preparing polymorphic forms of 3- [ 5-amino-4- (3-cyanobenzoyl) -pyrazol-1-yl ] -N-cyclopropyl-4-methylbenzamide | |
WO2016035018A1 (en) | Crystalline form of eltrombopag free acid | |
EP2032581B1 (en) | Enantiomerically enriched compounds and process | |
CZ2015277A3 (en) | Apremilast solid form and process for preparing thereof | |
TW201014845A (en) | Process for the stereoselective preparation of bicyclic heterocycles | |
WO2011039670A1 (en) | Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole) | |
KR20220127965A (en) | Manufacturing method for stable crystal form b of linagliptin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12700382 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2823103 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013547863 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012700382 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2012204839 Country of ref document: AU Date of ref document: 20120106 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13933198 Country of ref document: US |